Takeda bets up to $900M on Immusoft’s cell therapies for neurometabolic disorders

Immusoft has inked its first Big Pharma collaboration in a deal with biotech’s best friend Takeda worth up to $900 million that sees the pair work on cell therapies in rare inherited disorders. The pact will focus on neurometabolic disorders, Immusoft said Wednesday. The deal comes as the Seattle-based biotech nears the clinic for the first time in its decadelong journey working on sustained protein delivery for rare diseases. Read more >>